Sun, Dec 21, 2014, 4:08 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Toshiba Corporation Message Board

patworth123 3 posts  |  Last Activity: Oct 3, 2014 2:46 PM Member since: Oct 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    AMK Acquisition info

    by iknowhow2trade Oct 2, 2014 9:59 AM
    patworth123 patworth123 Oct 3, 2014 2:46 PM Flag

    If you are only holding for the dividend, you are investing in this company for the wrong reasons. Personally I would rather see no dividend and further acquisitions to enhance the bottom line revenue since that is truly when the growth will move the price higher.

    Sentiment: Buy

  • Reply to

    Solid Financials provide stability

    by patchen76 Sep 30, 2014 10:33 AM
    patworth123 patworth123 Sep 30, 2014 11:41 AM Flag

    Interestingly I just charted ALIM vs PSDV over 2 years. Agreed, the share price movement seemed lame relative to the approval, but if you look at the 2 companies ALIM has bounced and been beaten up over this time frame to have gained 100% where PSDV has gained 150%. I am in it for the long term and with the stability and tethadur in the wings I think the next year will be positive. When all is said and done: staying the course, letting the company gain market share and get up over the $5 barrier to the price where fund managers will begin to establish a position will serve all on the buy/hold side here very well.

  • patworth123 patworth123 Sep 23, 2014 10:08 PM Flag

    I am not sure where you are getting your information, but since the clinical trials website only indicated one ongoing and still unfinished phase 2 trial that is still recruiting patients, I believe IMHO you are misleading readers with no proof. I have no opinion on this company, but any serious investor in biotech's should familiarize him/herself with the clinical trials website.

4.22-0.03(-0.71%)Dec 19 3:28 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aegerion Pharmaceuticals, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
GrafTech International Ltd.
NYSEFri, Dec 19, 2014 4:11 PM EST